Related Experiment Video
Updated: Jun 5, 2026
09:02
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
Published on: June 5, 2020
Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?
Milan J Sonneveld1, Harry L A Janssen
1Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.
Summary
Pegylated interferon-α (PEG-IFN) offers a finite treatment for chronic hepatitis B (CHB) with sustained off-treatment responses. Optimizing patient selection can enhance PEG-IFN utilization in CHB management.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Pegylated interferon-α (PEG-IFN) remains a viable treatment for chronic hepatitis B (CHB), offering finite therapy and sustained responses.
- Potent nucleos(t)ide analogues (NUCs) like entecavir and tenofovir are first-line options but typically require long-term treatment due to low off-treatment durability.
Purpose of the Study:
- To evaluate the role of PEG-IFN in CHB treatment.
- To explore strategies for optimizing PEG-IFN use in CHB patients.
- To compare PEG-IFN with NUCs regarding treatment duration and response durability.
Main Methods:
- Review of current treatment guidelines and clinical trial data for PEG-IFN and NUCs in CHB.
- Analysis of factors influencing PEG-IFN response rates.
- Discussion of patient selection strategies for PEG-IFN therapy.
Main Results:
- PEG-IFN provides a limited treatment duration with a good probability of sustained off-treatment response, including HBsAg loss.
- NUCs offer a low resistance risk but generally have low off-treatment response durability, necessitating continuous therapy.
- Patient selection can improve response rates to PEG-IFN and allow early adaptation for non-responders.
Conclusions:
- PEG-IFN is a valuable option for CHB, particularly when sustained off-treatment response is desired.
- Advancements in patient selection promise to enhance the clinical utility of PEG-IFN in CHB management.
- Balancing PEG-IFN's benefits against NUCs' long-term requirements is crucial for personalized CHB therapy.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:29Viruses with RNA Genomes
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...